PhenoPath

PhenoPath is a well-established, pathologist-owned diagnostic laboratory and contract research organization (CRO) with over two decades of operational history. It leverages a deep bench of academically renowned pathologists to offer a broad menu of advanced diagnostic services, including specialized immunohistochemistry (IHC), flow cytometry, FISH, and molecular testing, with a strong focus on complex cancer diagnostics. The company operates a dual business model, providing critical diagnostic services to clinicians while also offering biomarker validation and development services to the biopharmaceutical industry for clinical trials and drug development. Its foundation is built on direct pathologist accessibility, peer-reviewed expertise, and a commitment to diagnostic accuracy.

Integrated diagnostic service platform utilizing a comprehensive menu of advanced techniques including specialized IHC (e.g., PD-L1), 10-color flow cytometry, FISH, cytogenetics, PCR, and NGS, supported by expert pathologist interpretation and biopharma assay validation services.

PhenoPath competes in the specialized reference laboratory market against large national players (Quest Diagnostics, LabCorp), academic medical center labs, and other niche oncology-focused labs. Its differentiation is its physician-owned structure, direct pathologist access, and deep academic expertise in specific cancer subtypes.